- Home
- BMRN vs GMAB Comparison
BMRN vs GMAB Comparison
Compare BMRN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- GMAB
- Stock Information
- Founded
- BMRN 1996
- GMAB 1999
- Country
- BMRN United States
- GMAB Denmark
- Employees
- BMRN N/A
- GMAB N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BMRN Health Care
- GMAB Health Care
- Exchange
- BMRN Nasdaq
- GMAB Nasdaq
- Market Cap
- BMRN 12.1B
- GMAB 13.7B
- IPO Year
- BMRN 1999
- GMAB N/A
- Fundamental
- Price
- BMRN $59.01
- GMAB $23.40
- Analyst Decision
- BMRN Buy
- GMAB Buy
- Analyst Count
- BMRN 23
- GMAB 7
- Target Price
- BMRN $93.73
- GMAB $37.80
- AVG Volume (30 Days)
- BMRN 1.8M
- GMAB 1.1M
- Earning Date
- BMRN 08-04-2025
- GMAB 08-07-2025
- Dividend Yield
- BMRN N/A
- GMAB N/A
- EPS Growth
- BMRN 152.82
- GMAB 276.80
- EPS
- BMRN 2.71
- GMAB 18.36
- Revenue
- BMRN $2,950,227,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- BMRN $12.27
- GMAB $747.74
- Revenue Next Year
- BMRN $9.99
- GMAB $14.81
- P/E Ratio
- BMRN $21.81
- GMAB $1.28
- Revenue Growth
- BMRN 19.36
- GMAB 25.43
- 52 Week Low
- BMRN $52.93
- GMAB $17.24
- 52 Week High
- BMRN $94.85
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- BMRN 55.66
- GMAB 67.34
- Support Level
- BMRN $56.48
- GMAB $21.59
- Resistance Level
- BMRN $60.43
- GMAB $23.87
- Average True Range (ATR)
- BMRN 1.52
- GMAB 0.38
- MACD
- BMRN 0.23
- GMAB 0.23
- Stochastic Oscillator
- BMRN 64.05
- GMAB 84.82
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.